Hybrid Nanostructured Oligonucleotide Platforms for Biomedical Applications Website


Nano-OligoMed, 2018
Nano-OligoMed, 2018

The Marie Curie - RISE 2017 H2020 Project: Hybrid Nanostructured Oligonucleotide Platforms for Biomedical Applications - Nano-OligoMed (778133) merges the expertise of research groups in seven institutions, four of them based in the European Union and the other three in America, the leadership in complementary research topics of the participant institutions and groups is one of the strengths of this project. Nano-Oligomed consortium is formed by the research groups of:

  • Prof. Luisa de Cola, University of Strasbourg, France
  • Prof. Hanadi Sleimann, McGill University, Canada
  • Prof. Nora Ventosa, Nanomol Technologies S.C., Spain
  • Prof. Marilyn Lanio, University of La Habana, Cuba
  • Prof. Alessandro Porchetta, University of Rome Tor Vergata, Italy
  • Prof. Michael J. Sailor, University of California San Diego, U.S.A.
  • Prof. Roberto Corriadini, University of Parma, Italy

The long-range goals of Nano-OligoMed involve three major objectives, Research, Training, and
Collaboration, which will be achieved through multidisciplinary scientific exchange, international mobility,
and strongly collaborative transfer of knowledge and training activities between Italy, USA, Spain, France,
Cuba and Canada.

The research objectives of the project are directed to achieve the development, optimization, and application of novel hybrid bio-responsive
nano/microstructured materials in which oligonucleotides serve as structural motifs and/or functional
payloads. This will ultimately result in the evaluation of in vitro and in vivo activity and therapeutic efficacy
of nanomedicines plugging the gap between innovative research in the field of functional hybrid
nanostructured materials and their exploitation in clinical setting for cancer therapeutic.